Teva Bids For BioXcel
BioXcel Therapeutics Files For Chapter 11 Bankruptcy And Names Teva As Stalking Horse Bidder
Anonymous
Key Points
1
BioXcel's DIP financing package contemplates up to $19 million in new term loans and a roll-up of approximately $58.25 million in prepetition debt, with the funding backed by lenders Oaktree and the Qatar Investment Authority.
2
Teva Pharmaceuticals will serve as the stalking horse bidder in the court-supervised sale, offering $57.5 million in cash plus up to $87.5 million in contingent milestone payments tied to IGALMI’s sNDA and post-closing sales; Teva’s bid is intended to anchor a Section 363 auction.
3
Samir Saleem was appointed as BioXcel’s Chief Restructuring Officer to oversee the restructuring and potential strategic transactions under the board's oversight.
4
BioXcel’s bankruptcy filing highlights a cash-strapped outlook: roughly $17.2 million in cash on hand as of March 31, with quarterly operating cash outflows around $11.8 million; Q2 revenue about $180,000 and net loss near $14.7 million, alongside an amended credit agreement adding about $1.25 million in new loans.
5
Investors reacted strongly to the news, with BioXcel shares dropping about 62% in premarket trading to around $0.27 and premarket volume approaching 975,000 shares.
BioXcel Therapeutics filed for Chapter 11 bankruptcy in Delaware, launching a court-supervised sale of its assets as the New Haven biotech company grapples with a severe cash crisis. Prism Market View reports that Teva Pharmaceuticals has been named the stalking horse bidder, offering $57.5 million upfront plus up to $87.5 million in contingent milestone payments tied to the company's IGALMI therapy and future sales.
BioXcel disclosed roughly $17.2 million in cash on hand as of March 31, with quarterly operating losses near $14.7 million and revenue barely reaching $180,000. TipRanks notes the company secured up to $19 million in debtor-in-possession financing backed by Oaktree and the Qatar Investment Authority, plus a $58.25 million roll-up of existing debt. BioXcel shares plunged 62% in premarket trading to around $0.27.
Teva's Strategic Bid Anchors the Auction
Teva Pharmaceuticals will lead the Section 363 auction as the stalking horse bidder with a base offer of $57.5 million in cash. Fierce Biotech reports the deal also includes contingent milestone payments up to $87.5 million tied to IGALMI's regulatory approvals and post-closing revenue performance. This structure gives Teva first-mover advantage while allowing other bidders to compete.
A Cash-Strapped Quarter Triggered the Collapse
BioXcel burned through cash at an unsustainable rate. In the most recent quarter, the company posted a net loss of $14.7 million against just $180,000 in revenue. Hartford Business indicates the company had roughly $17.2 million in cash, enough to cover only about 1.5 quarters of operating losses at current burn rates.
The company's liabilities likely exceed assets by hundreds of millions. Court filings show estimated assets between $10 million and $50 million, while liabilities may range from $100 million to $500 million. The amended credit agreement added $1.25 million in new loans, offering only temporary relief to a company facing structural insolvency.
Leadership and Restructuring Roadmap Established
Samir Saleem was appointed Chief Restructuring Officer to oversee the sale process and any strategic transactions. The board retained him to guide BioXcel through the auction and maximize recovery for creditors. City Biz notes the company will continue operations under court supervision while pursuing alternative bids beyond Teva's initial offer.
IGALMI and BXCL501 Become Prize Assets in Auction
BioXcel's neuroscience portfolio—centered on IGALMI (dexmedetomidine) and BXCL501—represents the company's core value in bankruptcy. Fierce Biotech reports these therapies target acute agitation in psychiatric settings and represent the company's most advanced commercial assets. Potential rival bidders may emerge to challenge Teva's offer and compete for these therapies during the auction process.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
51
Reach
64
A
AnonymousAuthor
